Almiba solution for oral administration in vials 10ml №10

Name:
Almiba.
Description:
Clear, colorless or pale yellow liquid. The main active ingredient is Levocarnitine. Release form Solution for oral administration. Dosage 100 mg / 1 ml 10 ml. Pharmacological group Amino acids and their derivatives. Indications for use Primary and secondary insufficiency of levocarnitine in adults, children, infants and newborns. Secondary deficiency of levocarnitine in patients with end-stage kidney disease who are on hemodialysis for a long time and are accompanied by the following conditions: severe and persistent muscle cramps and / or episodes of arterial hypotension during dialysis; muscle weakness and/or myopathy; cardiomyopathy; anemia with uremia, stable or requiring high doses of erythropoietin; loss of muscle mass caused by malnutrition. Dosage and administration The solution is for oral use only. The oral solution must be diluted with water or fruit juice before use. Used before meals. The recommended daily dose depends on the age and weight of the patient. Children under 12 The dose is determined according to body weight and depends on the severity of the patient’s condition. Usual dose: 100-200mg/kg/day divided into several doses (2 to 4). If there is no improvement in clinical and biochemical parameters, a short-term dose increase is possible. In some serious cases, doses up to 400 mg/kg/day may be used. Adults and children over 12 years of age The dose is determined according to body weight and depends on the severity of the patient’s condition. Usual dose: 100-200mg/kg/day divided into several doses (2 to 4). If there is no improvement in clinical and biochemical parameters, a short-term dose increase is possible. In some serious cases of acute metabolic decompensation, doses up to 400 mg/kg/day may be used. See the table below for dosage. You can use a teaspoon as a measuring spoon. 1 teaspoon contains 5 ml of oral solution. Age Daily dose in mg Daily dose in ml for oral form 0-1 year 150-500 mg 2.5-5.0 ml 1-3 years 500-1000 mg 5.0-10.0 ml 3-7 years 1000- 1500 mg 10.0 – 15.0 ml 7-12 years 1500-2000 mg 15.0 – 20.0 ml In children under one year of age by body weight. Use during pregnancy and lactation Experimental reproduction studies have shown the absence of any teratogenic effect. There are no data on the use of the drug in pregnant women against the background of primary carnitine deficiency. It is necessary to take into account the prevalence of the risk to the mother when discontinuing drug treatment over the theoretical risk to the fetus. Levocarnitine is a normal component of human milk. The use of levocarnitine in breastfeeding mothers has not been studied. Influence on the ability to drive a car or other mechanisms The drug does not affect the ability to drive vehicles and other potentially hazardous activities. Precautions With increased glucose utilization, the administration of levocarnitine to diabetic patients while taking insulin or hypoglycemic oral therapy may increase hypoglycemia. Plasma glucose levels should be monitored regularly for immediate adjustment of hypoglycemic therapy, if required. The safety and efficacy of treatment with oral levocarnitine cannot be assessed in patients with renal insufficiency. Long-term administration of high doses of oral levocarnitine to patients with various renal impairments or end-stage renal disease during hemodialysis can lead to the accumulation of toxic metabolites, trimethylamine and trimethylamine-n-oxide, since these metabolites are excreted in the urine. This situation is not observed with the / in the appointment of levocarnitine. Contraindications Hypersensitivity to the components of the drug. Composition 1 ml contains: 100 mg of levocarnitine; excipients: malic acid, sodium methylparaben E219, sodium propylparaben E217, sodium saccharin dihydrate, cherry flavor (propylene glycol, citric acid, water), water for injection. Overdose There are no data on the toxicity of levocarnitine in overdose. In case of an overdose, the tactics are generally accepted. Side effects With long-term use of levocarnitine orally, various mild gastrointestinal disorders have been reported, such as short-term nausea and vomiting, abdominal cramps and diarrhea. Moderate myasthenia gravis has only been described in uremic patients treated with levocarnitine. Reducing the dosage often reduces or completely eliminates the observed gastrointestinal symptoms. Tolerability should be checked during the first week of use and after any increase in dosage. Storage conditions Store below 25°C, protected from light. Keep out of the reach of children. Buy Almiba oral solution in vials 10ml №10 Price for Almiba oral solution in vials 10ml №10